Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Pluristem Therapeutics Inc.    PSTI

 SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/17/2017 07/18/2017 07/19/2017 07/20/2017 07/21/2017 Date
1.19(c) 1.2(c) 1.18(c) 1.18(c) 1.2(c) Last
239 916 81 117 181 372 146 433 141 470 Volume
-4.03% +0.84% -1.67% 0.00% +1.69% Change
More quotes
Financials ($)
Sales 2017 -
EBIT 2017 -27,8 M
Net income 2017 -27,8 M
Debt 2017 -
Yield 2017 -
Sales 2018 -
EBIT 2018 -33,5 M
Net income 2018 -34,0 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 0
Capi. / Sales2018 0
Capitalization 116 M
More Financials
Company
Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development.It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others.Its products include PLacental... 
More about the company
Latest news on PLURISTEM THERAPEUTICS INC
07/10 Pluristem Advances its Multinational Phase III Critical Limb Ischemia Study, ..
07/07 PLURISTEM THERAPEUTICS INC : Entry into a Material Definitive Agreement, Financi..
06/29 Pluristem to Present New Data from ARS study at Radiology Conference in U.S.
06/23 PLURISTEM THERAPEUTICS INC. (NASDAQ : PSTI) Files An 8-K Departure of Directors ..
06/23 PLURISTEM THERAPEUTICS INC : Change in Directors or Principal Officers (form 8-K..
06/22 PLURISTEM THERAPEUTICS : China's Innovative Medical cancels Pluristem investment
06/20 PLURISTEM THERAPEUTICS INC : Other Events (form 8-K)
05/26 PLURISTEM THERAPEUTICS : The Israeli company protecting against radiation catast..
05/25 PLURISTEM THERAPEUTICS INC. (NASDAQ : PSTI) Files An 8-K Submission of Matters t..
05/25 PLURISTEM THERAPEUTICS INC : Submission of Matters to a Vote of Security Holders..
More news
Sector news : Biotechnology & Medical Research - NEC
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
07/143 Things In Biotech You Should Learn Today: July 14, 2017  
07/12Pluristem Therapeutics, Inc. $PSTI Given a $2.00 Price Target by Maxim Group .. 
07/11Oppenheimer & Co. Inc. Has $156,000 Position in Pluristem Therapeutics, I.. 
07/10Maxim Group Reaffirms “Buy” Rating for Pluristem Therapeutics, Inc. $PSTI  
07/10Pluristem Therapeutics's buy rating reiterated at Maxim Group. $2.00 PT.  
More tweets
Qtime:12
News from SeekingAlpha
07/14 3 THINGS IN BIOTECH YOU SHOULD LEARN : July 14, 2017
06/20 Chinese investor backs off $30M investment in Pluristem; shares down 4% after..
05/03 PREMARKET GAINERS AS OF 9 : 05 am
05/03 Pluristem +10% on promising results for PLX-R18
04/11 Can Pluristem Therapeutics Corner The Acute Radiation Syndrome Market?
Chart PLURISTEM THERAPEUTICS INC
Duration : Period :
Pluristem Therapeutics Inc Technical Analysis Chart | PSTI | US72940R1023 | 4-Traders
Technical analysis trends PLURISTEM THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 2
Average target price 2,75 $
Spread / Average Target 129%
EPS Revisions
Managers
NameTitle
Zami Aberman Chairman & Co-Chief Executive Officer
Yaky Yanay President, Co-Chief Executive Officer & Director
Sagi Moran Vice President-Operations
Erez Egozi Chief Financial Officer & Treasurer
Esther Lukasiewicz-Hagai Vice President-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
PLURISTEM THERAPEUTICS INC.-16.08%116
INCYTE CORPORATION33.86%27 485
QUINTILES IMS HOLDINGS INC19.86%19 672
LONZA GROUP31.59%16 914
CELLTRION, INC.--.--%12 564
ALKERMES PLC3.87%8 844